<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>14</Volume>
				<Issue>4</Issue>
				<PubDate PubStatus="epublish">
					<Year>2013</Year>
					<Month>04</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Potential Targets for Prevention of Colorectal Cancer: a Focus on PI3K/Akt/mTOR and Wnt Pathways</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>2201</FirstPage>
			<LastPage>2205</LastPage>
			<ELocationID EIdType="pii">27599</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>Colorectal cancer (CRC) is one of the most common cancers in many parts of the world. Its development is a multi-step process involving three distinct stages, initiation that alters the molecular message of a normal cell, followed by promotion and progression that ultimately generates a phenotypically altered transformed malignant cell. Reports have suggested an association of the phosphoinositide-3-kinase (PI3K)/Akt pathway with colon tumorigenesis. Activation of Akt signaling and impaired expression of phosphatase and tensin homolog (PTEN) (a negative regulator of Akt) has been reported in 60-70% of human colon cancers and inhibitors of PI3K/Akt signaling have been suggested as potential therapeutic agents. Around 80% of human colon tumors possess mutations in the APC gene and half of the remainder feature β-catenin gene mutations which affect downstream signaling of the PI3K/Akt pathway. In recent years, there has been a great focus in targeting these signaling pathways, with natural and synthetic drugs reducing the tumor burden in different experiment models. In this review we survey the role of PI3K/Akt/mTOR and Wnt signaling in CRC.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Colon cancer</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">PI3K/Akt</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">mTOR</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Wnt/β-catenin</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Chemoprevention</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Flavonoids</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_27599_6f11cd925b3fe61db6eeb8b14f5ef6d3.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
